Iovance Biotherapeutics, Inc. (IOVA) EPS Estimated At $-0.34

October 2, 2018 - By Hazel Jackson

Analysts expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to report $-0.34 EPS on October, 30.They anticipate $0.01 EPS change or 2.86 % from last quarter’s $-0.35 EPS. After having $-0.34 EPS previously, Iovance Biotherapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.71% or $0.19 during the last trading session, reaching $10.93. About 183,387 shares traded. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has risen 80.69% since October 2, 2017 and is uptrending. It has outperformed by 65.07% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.05 billion. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More news for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were recently published by: Seekingalpha.com, which released: “Key events next week – healthcare” on September 21, 2018. Seekingalpha.com‘s article titled: “Iovance Bio down 12% premarket following presentation of TIL data in lung cancer” and published on September 06, 2018 is yet another important article.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>